Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults With DSM5 Current Cannabis Use Disorder (CUD)

NCT03386487 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT03386487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03386487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults With DSM5 Current Cannabis Use Disorder (CUD)
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Completed
Start date
January 14, 2019
Completion date
July 25, 2022
Enrollment
228 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cannabis use disorder